Brain Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Brain Cancer, including details on symptoms, benign and malignant tumors, gliomas, treatment.

Volume 8 (2011), Issue 5 (May)

1. Pilomyxoid astrocytoma of the cerebellum.
   J Neurosurg Pediatr, 7(5): 539-42. [Abstract] [Full-text]
2. Papillary tumor of the pineal region in a 15-month-old boy.
   J Neurosurg Pediatr, 7(5): 534-8. [Abstract] [Full-text]
3. Posterior interhemispheric retrocallosal approach to pineal region and posterior fossa lesions in a pediatric population.
   J Neurosurg Pediatr, 7(5): 527-33. [Abstract] [Full-text]
4. Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride.
   J Neurosurg Pediatr, 7(5): 522-6. [Abstract] [Full-text]
5. Use of a minimally invasive tubular retraction system for deep-seated tumors in pediatric patients.
   J Neurosurg Pediatr, 7(5): 516-21. [Abstract] [Full-text]
6. Nonneoplastic enlargement of the pituitary gland in children.
   J Neurosurg Pediatr, 7(5): 510-5. [Abstract] [Full-text]
7. Microscopic endonasal transsphenoidal pituitary adenomectomy in the pediatric population.
   J Neurosurg Pediatr, 7(5): 501-9. [Abstract] [Full-text]
8. Congenital brain tumors: diagnostic pitfalls and therapeutic interventions.
   J Child Neurol, 26(5): 599-614. [Abstract] [Full-text]
9. Tumoricidal bystander effect in the suicide gene therapy using mesenchymal stem cells does not injure normal brain tissues.
   Cancer Lett, 306(1): 99-105. [Abstract] [Full-text]
10. Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth.
    Brain Res, 1390: 21-32. [Abstract] [Full-text]
11. Evidence for potentials and limitations of brain plasticity using an atlas of functional resectability of WHO grade II gliomas: towards a "minimal common brain".
    Neuroimage, 56(3): 992-1000. [Abstract] [Full-text]
12. Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
    Int J Radiat Biol, 87(5): 518-33. [Abstract] [Full-text]
13. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs.
    Cancer Res, 71(9): 3387-99. [Abstract] [Full-text]
14. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
    Acta Neuropathol, 121(5): 651-61. [Abstract] [Full-text]
15. Primary glioblastoma of the cerebellopontine angle in adults.
    J Neurosurg, 114(5): 1288-93. [Abstract] [Full-text]
16. The neurosurgical anatomy of the sphenoid sinus and sellar floor in endoscopic transsphenoidal surgery.
    J Neurosurg, 114(5): 1319-30. [Abstract] [Full-text]
17. Technique and outcome of endoscopy-assisted microscopic extended transsphenoidal surgery for suprasellar craniopharyngiomas.
    J Neurosurg, 114(5): 1338-49. [Abstract] [Full-text]
18. Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series.
    J Neurosurg, 114(5): 1350-9. [Abstract] [Full-text]
19. Dopamine agonist-resistant prolactinomas.
    J Neurosurg, 114(5): 1369-79. [Abstract] [Full-text]
20. A novel transnasal transsphenoidal speculum: a design for both microscopic and endoscopic transsphenoidal pituitary surgery.
    J Neurosurg, 114(5): 1380-5. [Abstract] [Full-text]
21. Vascular endothelial growth factor increases permeability of the blood-tumor barrier via caveolae-mediated transcellular pathway.
    J Mol Neurosci, 44(2): 122-9. [Abstract] [Full-text]
22. Use of 5-ALA fluorescence guided endoscopic biopsy of a deep-seated primary malignant brain tumor.
    J Neurosurg, 114(5): 1410-3. [Abstract] [Full-text]
23. Long-term outcome after resection of brainstem hemangioblastomas in von Hippel-Lindau disease.
    J Neurosurg, 114(5): 1312-8. [Abstract] [Full-text]
24. Image-guided frameless stereotactic needle biopsy in awake patients without the use of rigid head fixation.
    J Neurosurg, 114(5): 1414-20. [Abstract] [Full-text]
25. Preservation of the superior petrosal sinus during the petrosal approach.
    J Neurosurg, 114(5): 1294-8. [Abstract] [Full-text]
26. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.
    J Surg Res, 168(1): 97-102. [Abstract] [Full-text]
27. Recurrence rates after neuroendoscopic fenestration and Gamma Knife surgery in comparison with subtotal resection and Gamma Knife surgery for the treatment of cystic craniopharyngiomas.
    J Neurosurg, 114(5): 1360-8. [Abstract] [Full-text]
28. The mixed human umbilical cord blood-derived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro.
    Neurol Res, 33(4): 405-14. [Abstract] [Full-text]
29. POTEH hypomethylation, a new epigenetic biomarker for glioma prognosis.
    Brain Res, 1391: 125-31. [Abstract] [Full-text]
30. Metabolic management of brain cancer.
    Biochim Biophys Acta, 1807(6): 577-94. [Abstract] [Full-text]
31. Analysis of differential gene expression by bead-based fiber-optic array in nonfunctioning pituitary adenomas.
    Horm Metab Res, 43(5): 325-30. [Abstract] [Full-text]
32. Intracranial hemangiopericytoma: Case study with cytogenetics and genome wide SNP-A analysis.
    Pathol Res Pract, 207(5): 310-6. [Abstract] [Full-text]
33. Differentiating cerebellar and brainstem lesions with ocular vestibular-evoked myogenic potential test.
    Eur Arch Otorhinolaryngol, 268(6): 923-30. [Abstract] [Full-text]
34. Intersectin1-s is involved in migration and invasion of human glioma cells.
    J Neurosci Res, 89(7): 1079-90. [Abstract] [Full-text]
35. Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality.
    J Clin Endocrinol Metab, 96(5): 1524-32. [Abstract] [Full-text]
36. Notch1 is an independent prognostic factor for patients with glioma.
    J Surg Oncol, 103(8): 813-7. [Abstract] [Full-text]
37. Somnolence in adult craniopharyngioma patients is a common, heterogeneous condition that is potentially treatable.
    Clin Endocrinol (Oxf), 74(6): 750-5. [Abstract] [Full-text]
38. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
    Clin Endocrinol (Oxf), 74(6): 736-43. [Abstract] [Full-text]
39. Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas.
    Expert Opin Biol Ther, 11(6): 799-806. [Abstract] [Full-text]
40. Supratentorial PNET in a young child.
    Indian J Pediatr, 78(5): 613-5. [Abstract] [Full-text]
41. Magnetic resonance spectroscopic imaging for visualization of the infiltration zone of glioma.
    Cent Eur Neurosurg, 72(2): 63-9. [Abstract] [Full-text]
42. Proteomics studies of childhood pilocytic astrocytoma.
    J Proteome Res, 10(5): 2555-65. [Abstract] [Full-text]
43. Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006.
    J Neurooncol, 102(3): 459-69. [Abstract] [Full-text]
44. An NF-κB p65-cIAP2 link is necessary for mediating resistance to TNF-α induced cell death in gliomas.
    J Neurooncol, 102(3): 367-81. [Abstract] [Full-text]
45. L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a Phase I study.
    Int J Radiat Oncol Biol Phys, 80(2): 369-76. [Abstract] [Full-text]
46. Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease.
    J Neurooncol, 103(1): 1-17. [Abstract] [Full-text]
47. Which therapy works better in choroid plexus carcinomas?
    J Neurooncol, 103(1): 155-62. [Abstract] [Full-text]
48. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
    J Neurooncol, 102(3): 353-66. [Abstract] [Full-text]
49. Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases.
    J Neurooncol, 102(3): 477-84. [Abstract] [Full-text]
50. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis.
    J Neurooncol, 103(1): 137-46. [Abstract] [Full-text]
51. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids.
    J Neurooncol, 103(1): 43-58. [Abstract] [Full-text]
52. Health-related quality of life and cognitive functioning in adult patients with supratentorial WHO grade II glioma: status prior to therapy.
    J Neurooncol, 103(1): 129-36. [Abstract] [Full-text]
53. Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
    J Neurooncol, 103(1): 59-69. [Abstract] [Full-text]
54. Whole-genomic survey of oligodendroglial tumors: correlation between allelic imbalances and gene expression profiles.
    J Neurooncol, 103(1): 71-85. [Abstract] [Full-text]
55. Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.
    J Neurooncol, 103(1): 87-102. [Abstract] [Full-text]
56. Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
    J Neurooncol, 103(1): 147-53. [Abstract] [Full-text]
57. A case of soft tissue metastasis from glioblastoma and review of the literature.
    J Neurooncol, 103(1): 167-72. [Abstract] [Full-text]
58. Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies.
    J Neurooncol, 102(3): 395-407. [Abstract] [Full-text]
59. Supratentorial and cerebellar liponeurocytomas: report of four cases with review of literature.
    J Neurooncol, 103(1): 121-7. [Abstract] [Full-text]
60. Papillary endothelial hyperplasia presenting as recurrent malignant glioma.
    J Neurooncol, 102(3): 491-8. [Abstract] [Full-text]
61. Hepatic encephalopathy after treatment with temozolomide.
    J Neurooncol, 103(1): 163-6. [Abstract] [Full-text]
62. Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma.
    J Neurooncol, 103(1): 19-31. [Abstract] [Full-text]
63. Optic pathway ganglioglioma with intraventricular cyst.
    J Neurooncol, 102(3): 499-508. [Abstract] [Full-text]
64. Factors impacting volumetric white matter changes following whole brain radiation therapy.
    J Neurooncol, 103(1): 111-9. [Abstract] [Full-text]
65. Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.
    J Neurooncol, 102(3): 443-9. [Abstract] [Full-text]
66. Intracranial ependymomas treated with radiotherapy: long-term results from a single institution.
    J Neurooncol, 102(3): 451-7. [Abstract] [Full-text]
67. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
    J Neurooncol, 102(3): 417-24. [Abstract] [Full-text]
68. High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study.
    J Neurooncol, 102(3): 433-42. [Abstract] [Full-text]
69. Differential kinetics of α-[¹¹C]methyl-L-tryptophan on PET in low-grade brain tumors.
    J Neurooncol, 102(3): 409-15. [Abstract] [Full-text]
70. Minimized doses for linear accelerator radiosurgery of brainstem metastasis.
    Int J Radiat Oncol Biol Phys, 80(2): 362-8. [Abstract] [Full-text]
71. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
    Int J Radiat Oncol Biol Phys, 80(2): 347-53. [Abstract] [Full-text]
72. Molecular cytogenetic analysis of a gliosarcoma with osseous metaplasia.
    Cytogenet Genome Res, 134(2): 88-95. [Abstract] [Full-text]
73. Risk-adapted chemotherapy in childhood medulloblastoma.
    Expert Rev Anticancer Ther, 11(5): 771-80. [Abstract] [Full-text]
74. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo.
    BMC Cancer, 11: 144. [Abstract] [Full-text]
75. Vertebral fractures in males with prolactinoma.
    Endocrine, 39(3): 288-93. [Abstract] [Full-text]
76. Comparison of time taken from initial presentation to histological diagnosis of Glioblastoma Multiforme (GBM) in Birmingham, United Kingdom and Strasbourg, France.
    Clin Neurol Neurosurg, 113(5): 358-61. [Abstract] [Full-text]
77. Matrix metalloproteinase 2 attenuates brain tumour growth, while promoting macrophage recruitment and vascular repair.
    J Pathol, 224(2): 222-33. [Abstract] [Full-text]
78. ADHD and secondary ADHD criteria fail to identify many at-risk survivors of pediatric ALL and brain tumor.
    Pediatr Blood Cancer, 57(1): 110-8. [Abstract] [Full-text]
79. Identification of venous variants in the pineal region with three-dimensional preoperative magnetic resonance imaging navigation in patients harbouring tumors in this area: significance for surgical approach to the lesion.
    Clin Neurol Neurosurg, 113(5): 387-92. [Abstract] [Full-text]
80. Glioblastoma multiforme in the Muir-Torre syndrome.
    Clin Neurol Neurosurg, 113(5): 411-5. [Abstract] [Full-text]
81. Glioblastoma multiforme at the corpus callosum with spinal leptomeningeal metastasis.
    Clin Neurol Neurosurg, 113(5): 407-10. [Abstract] [Full-text]
82. Atypical teratoid/rhabdoid tumor: short clinical description and insight into possible mechanism of the disease.
    Eur J Neurol, 18(6): 813-8. [Abstract] [Full-text]
83. The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
    Childs Nerv Syst, 27(6): 897-901. [Abstract] [Full-text]
84. TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma.
    PLoS One, 6(4): e18608. [Abstract] [Full-text]
85. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.
    PLoS One, 6(4): e18490. [Abstract] [Full-text]
86. High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma.
    Neuro Oncol, 13(5): 500-8. [Abstract] [Full-text]
87. Incidence of vasculopathy in children with hypothalamic/chiasmatic gliomas treated with brachytherapy.
    Childs Nerv Syst, 27(6): 961-6. [Abstract] [Full-text]
88. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
    Neuro Oncol, 13(5): 471-86. [Abstract] [Full-text]
89. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
    Neuro Oncol, 13(5): 509-16. [Abstract] [Full-text]
90. Pretreatment neuropsychological deficits in children with brain tumors.
    Neuro Oncol, 13(5): 517-24. [Abstract] [Full-text]
91. Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes.
    Neuro Oncol, 13(5): 536-45. [Abstract] [Full-text]
92. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
    Neuro Oncol, 13(5): 487-99. [Abstract] [Full-text]
93. Chromosome 9q and 16q loss identified by genome-wide pooled-analysis are associated with tumor aggressiveness in patients with classic medulloblastoma.
    OMICS, 15(5): 273-80. [Abstract] [Full-text]
94. Neuroendoscopy in the management of pineal tumors.
    Childs Nerv Syst, 27(6): 949-59. [Abstract] [Full-text]
95. Presence of glioma stroma mesenchymal stem cells in a murine orthotopic glioma model.
    Childs Nerv Syst, 27(6): 911-22. [Abstract] [Full-text]
96. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.
    Neuro Oncol, 13(5): 546-57. [Abstract] [Full-text]
97. Non-functioning pituitary adenomas: a single center experience.
    Exp Clin Endocrinol Diabetes, 119(5): 314-9. [Abstract] [Full-text]
98. Short-term neurological outcome of children after surgery for brain tumors: incidence and characteristics in a pediatric intensive care unit.
    Childs Nerv Syst, 27(6): 933-41. [Abstract] [Full-text]
99. Image denoising methods for tumor discrimination in high-resolution computed tomography.
    J Digit Imaging, 24(3): 464-9. [Abstract] [Full-text]
100. Retrospective evaluation of PET-MRI registration algorithms.
     J Digit Imaging, 24(3): 485-93. [Abstract] [Full-text]
101. Hemophagocytic lymphohistiocytosis with neurological presentation: MRI findings and a nearly miss diagnosis.
     Neurol Sci, 32(3): 473-7. [Abstract] [Full-text]
102. Hypofractionated stereotactic radiotherapy for oligometastases in the brain: a single-institution experience.
     Neurol Sci, 32(3): 393-9. [Abstract] [Full-text]
103. Solitary fibrous tumor of the orbit with intracranial involvement.
     Ophthal Plast Reconstr Surg, 27(3): e74-6. [Abstract] [Full-text]
104. Clinical significance of anaemia associated with prolactin-secreting pituitary tumours in men.
     Int J Clin Pract, 65(6): 669-73. [Abstract] [Full-text]
105. Extraventricular neurocytomas: a morphological and histogenetic consideration. A study of six cases.
     Pathology, 43(4): 327-34. [Abstract] [Full-text]
106. Mitotic arrest deficient protein MAD2B is overexpressed in human glioma, with depletion enhancing sensitivity to ionizing radiation.
     J Clin Neurosci, 18(6): 827-33. [Abstract] [Full-text]
107. Histone acetylation patterns of typical and atypical pituitary adenomas indicate epigenetic shift of these tumours.
     J Neuroendocrinol, 23(6): 525-30. [Abstract] [Full-text]
108. Pineal anlage tumour - a rare entity with divergent histology.
     J Clin Neurosci, 18(6): 811-3. [Abstract] [Full-text]
109. Treatment of brain metastases from germ cell tumors.
     Hematol Oncol Clin North Am, 25(3): 605-13, ix. [Abstract] [Full-text]
110. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression.
     Am J Surg Pathol, 35(6): 933-5. [Abstract] [Full-text]
111. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases.
     Am J Surg Pathol, 35(6): 845-52. [Abstract] [Full-text]
112. Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.
     Oncol Rep, 26(1): 281-6. [Abstract] [Full-text]
113. Neuroepithelial stem cell marker nestin regulates the migration, invasion and growth of human gliomas.
     Oncol Rep, 26(1): 91-9. [Abstract] [Full-text]
114. The prostate stem cell antigen represents a novel glioma-associated antigen.
     Oncol Rep, 26(1): 13-21. [Abstract] [Full-text]
115. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo.
     BMC Cancer, 11: 136. [Abstract] [Full-text]
116. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.
     AJNR Am J Neuroradiol, 32(5): 882-9. [Abstract] [Full-text]
117. Endoscopic endonasal approach for pituitary adenoma: surgical complications in 301 patients.
     Pituitary, 14(2): 174-83. [Abstract] [Full-text]
118. Inhibin B and anti-Müllerian hormone as markers of gonadal function after treatment for medulloblastoma or posterior fossa ependymoma during childhood.
     J Pediatr, 158(6): 1016-1022.e1. [Abstract] [Full-text]
119. Transnasal trans-sphenoidal endoscopic repair of CSF leak secondary to invasive pituitary tumours using a nasoseptal flap.
     Pituitary, 14(2): 163-7. [Abstract] [Full-text]
120. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.
     Pituitary, 14(2): 141-7. [Abstract] [Full-text]
121. MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas.
     Pituitary, 14(2): 112-24. [Abstract] [Full-text]
122. Integrating functional MRI information into radiotherapy planning of CNS tumors-early experiences.
     Pathol Oncol Res, 17(2): 207-17. [Abstract] [Full-text]
123. Combined antitumor effect of Ad-bFGF-siRNA and Ad-Vpr on the growth of xenograft glioma in nude mouse model.
     Pathol Oncol Res, 17(2): 237-42. [Abstract] [Full-text]
124. Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus.
     Pituitary, 14(2): 194-7. [Abstract] [Full-text]
125. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
     Acta Oncol, 50(5): 630-5. [Abstract] [Full-text]
126. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
     J Pharmacol Exp Ther, 337(3): 766-74. [Abstract] [Full-text]
127. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
     Clin Cancer Res, 17(10): 3282-92. [Abstract] [Full-text]
128. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
     Clin Cancer Res, 17(10): 3233-47. [Abstract] [Full-text]
129. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.
     J Magn Reson Imaging, 33(6): 1284-90. [Abstract] [Full-text]
130. Intra-fraction setup variability: IR optical localization vs. X-ray imaging in a hypofractionated patient population.
     Radiat Oncol, 6: 38. [Abstract] [Full-text]
131. Combining phase images from multi-channel RF coils using 3D phase offset maps derived from a dual-echo scan.
     Magn Reson Med, 65(6): 1638-48. [Abstract] [Full-text]
132. Adolescent cancer survivors' smoking intentions are associated with aggression, attention, and smoking history.
     J Cancer Surviv, 5(2): 123-31. [Abstract] [Full-text]
133. GLI2 is a potential therapeutic target in pediatric medulloblastoma.
     J Neuropathol Exp Neurol, 70(6): 430-7. [Abstract] [Full-text]
134. Magnetic resonance imaging spectrum of medulloblastoma.
     Neuroradiology, 53(6): 387-96. [Abstract] [Full-text]
135. Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
     J Neurooncol, 103(2): 361-70. [Abstract] [Full-text]
136. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
     J Neurooncol, 103(2): 343-51. [Abstract] [Full-text]
137. Measurements of diagnostic examination performance and correlation analysis using microvascular leakage, cerebral blood volume, and blood flow derived from 3T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in glial tumor grading.
     Neuroradiology, 53(6): 435-47. [Abstract] [Full-text]
138. KIT expression and methylation in medulloblastoma and PNET cell lines and tumors.
     J Neurooncol, 103(2): 247-53. [Abstract] [Full-text]
139. Human hedgehog interacting protein expression and promoter methylation in medulloblastoma cell lines and primary tumor samples.
     J Neurooncol, 103(2): 287-96. [Abstract] [Full-text]
140. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
     J Neurooncol, 103(2): 371-9. [Abstract] [Full-text]
141. Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors.
     J Neurooncol, 103(2): 175-85. [Abstract] [Full-text]
142. Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
     J Neurooncol, 103(2): 353-60. [Abstract] [Full-text]
143. Primary central nervous system extranodal NK/T-cell lymphoma, nasal type: case report and review of the literature.
     J Neurooncol, 103(2): 387-91. [Abstract] [Full-text]
144. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme.
     J Neurooncol, 103(2): 317-24. [Abstract] [Full-text]
145. Ventriculoperitoneal shunt complications in hydrocephalus patients with intracranial tumors: an analysis of relevant risk factors.
     J Neurooncol, 103(2): 333-42. [Abstract] [Full-text]
146. Links between private habits, psychological stress and brain cancer: a case-control pilot study in France.
     J Neurooncol, 103(2): 307-16. [Abstract] [Full-text]
147. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
     J Neurooncol, 103(2): 255-66. [Abstract] [Full-text]
148. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
     J Neurooncol, 103(2): 325-32. [Abstract] [Full-text]
149. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.
     J Neurooncol, 103(2): 221-30. [Abstract] [Full-text]
150. The detection of CMV pp65 and IE1 in glioblastoma multiforme.
     J Neurooncol, 103(2): 231-8. [Abstract] [Full-text]
151. De novo malignant craniopharyngioma: case report and literature review.
     J Neurooncol, 103(2): 381-6. [Abstract] [Full-text]
152. Clinical significance of thallium-201 SPECT after postoperative radiotherapy in patients with glioblastoma multiforme.
     J Neurooncol, 103(2): 297-305. [Abstract] [Full-text]
153. Characterization of signaling function and expression of HLA class I molecules in medulloblastoma.
     J Neurooncol, 103(2): 197-206. [Abstract] [Full-text]
154. MR imaging characteristics of protoplasmic astrocytomas.
     Neuroradiology, 53(6): 405-11. [Abstract] [Full-text]
155. Relationship between the brain radiation dose for the treatment of childhood cancer and the risk of long-term cerebrovascular mortality.
     Brain, 134: 1362-72. [Abstract] [Full-text]
156. Evidence for label-retaining tumour-initiating cells in human glioblastoma.
     Brain, 134: 1331-43. [Abstract] [Full-text]
157. Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma.
     J Neuroinflammation, 8: 32. [Abstract] [Full-text]
158. Spreading depolarizations have prolonged direct current shifts and are associated with poor outcome in brain trauma.
     Brain, 134: 1529-40. [Abstract] [Full-text]
159. Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases.
     J Oncol Pharm Pract, 17(2): 141-4. [Abstract] [Full-text]
160. The impact of provider surgical volumes on survival in children with primary tumors of the central nervous system--a population-based study.
     Acta Neurochir (Wien), 153(6): 1219-29; discussion 1229. [Abstract] [Full-text]
161. Knockdown of TFPI-2 promotes migration and invasion of glioma cells.
     Neurosci Lett, 497(1): 49-54. [Abstract] [Full-text]
162. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
     Acta Neurochir (Wien), 153(6): 1211-8. [Abstract] [Full-text]
163. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients.
     J Clin Endocrinol Metab, 96(6): 1633-41. [Abstract] [Full-text]
164. Aberrant expression of thyroid hormone receptor beta isoform may cause inappropriate secretion of TSH in a TSH-secreting pituitary adenoma.
     J Clin Endocrinol Metab, 96(6): E948-52. [Abstract] [Full-text]
165. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
     Acta Neuropathol, 121(6): 763-74. [Abstract] [Full-text]
166. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
     Acta Neuropathol, 121(6): 753-61. [Abstract] [Full-text]
167. Impact of random and systematic recall errors and selection bias in case--control studies on mobile phone use and brain tumors in adolescents (CEFALO study).
     Bioelectromagnetics, 32(5): 396-407. [Abstract] [Full-text]
168. Time trends (1998-2007) in brain cancer incidence rates in relation to mobile phone use in England.
     Bioelectromagnetics, 32(5): 334-9. [Abstract] [Full-text]
169. Radiation-induced olfactory neuroblastoma: a new etiology is possible.
     Oral Maxillofac Surg, 15(2): 71-7. [Abstract] [Full-text]
170. Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma.
     Fam Cancer, 10(2): 337-42. [Abstract] [Full-text]
171. Advances in treatment techniques: arc-based and other intensity modulated therapies.
     Cancer J, 17(3): 166-76. [Abstract] [Full-text]
172. PROX1 is a predictor of survival for gliomas WHO grade II.
     Br J Cancer, 104(11): 1747-54. [Abstract] [Full-text]
173. HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats.
     Eur J Drug Metab Pharmacokinet, 36(2): 61-9. [Abstract] [Full-text]
174. SMART syndrome: a late reversible complication after radiation therapy for brain tumours.
     J Neurol, 258(6): 1098-104. [Abstract] [Full-text]
175. Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancement.
     Eur Radiol, 21(7): 1526-34. [Abstract] [Full-text]
176. Diagnostic benefits of presurgical fMRI in patients with brain tumours in the primary sensorimotor cortex.
     Eur Radiol, 21(7): 1517-25. [Abstract] [Full-text]
177. Relationship between extracellular osmolarity, NaCl concentration and cell volume in rat glioma cells.
     Gen Physiol Biophys, 30(2): 162-6. [Abstract] [Full-text]
178. Medical diagnostic radiation exposures and risk of gliomas.
     Radiat Res, 175(6): 790-6. [Abstract] [Full-text]
179. Calcium dependence of purinergic subtype P2Y₁ receptor modulation of C6 glioma cell migration.
     Neurosci Lett, 497(2): 80-4. [Abstract] [Full-text]
180. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
     Exp Cell Res, 317(11): 1513-26. [Abstract] [Full-text]
181. PHACE without face? Infantile hemangiomas of the upper body region with minimal or absent facial hemangiomas and associated structural malformations.
     Pediatr Dermatol, 28(3): 235-41. [Abstract] [Full-text]
182. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
     Int J Cancer, 129(3): 659-70. [Abstract] [Full-text]
183. Interaction of ASIC1 and ENaC subunits in human glioma cells and rat astrocytes.
     Am J Physiol Cell Physiol, 300(6): C1246-59. [Abstract] [Full-text]
184. Listeria monocytogenes encephalitis: an unusual cause of reversible confusion in a patient with glioblastoma multiforme.
     Br J Neurosurg, 25(3): 333-4. [Abstract] [Full-text]
185. Anaplastic astrocytoma with angiocentric ependymal differentiation.
     Neuropathology, 31(3): 292-8. [Abstract] [Full-text]
186. Human glioblastoma-initiating cells invade specifically the subventricular zones and olfactory bulbs of mice after striatal injection.
     Int J Cancer, 129(3): 574-85. [Abstract] [Full-text]
187. Low-grade recurrence of a congenital high-grade supratentorial tumor with astrocytic features in the absence of adjuvant therapy.
     Neuropathology, 31(3): 286-91. [Abstract] [Full-text]
188. Pituitary adenoma and incidental superior hypophyseal aneurysm.
     Br J Neurosurg, 25(3): 432-3. [Abstract] [Full-text]
189. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465.
     J Nucl Med, 52(6): 986-93. [Abstract] [Full-text]
190. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
     J Nucl Med, 52(6): 856-64. [Abstract] [Full-text]
191. Pulsed high-intensity focused ultrasound enhances the relative permeability of the blood-tumor barrier in a glioma-bearing rat model.
     IEEE Trans Ultrason Ferroelectr Freq Control, 58(5): 964-70. [Abstract] [Full-text]
192. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation.
     J Nucl Med, 52(6): 865-72. [Abstract] [Full-text]
193. MicroPET/CT imaging of an orthotopic model of human glioblastoma multiforme and evaluation of pulsed low-dose irradiation.
     Int J Radiat Oncol Biol Phys, 80(3): 885-92. [Abstract] [Full-text]
194. Unusual anatomic location of a primary intracranial yolk sac tumor.
     Ann Saudi Med, 31(3): 298-300. [Abstract] [Full-text]
195. Infant ependymoma in a 10-year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) experience with omitted or deferred radiotherapy.
     Int J Radiat Oncol Biol Phys, 80(3): 807-14. [Abstract] [Full-text]
196. Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer.
     Onkologie, 34(6): 304-8. [Abstract] [Full-text]
197. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.
     Neurology, 76(22): 1918-24. [Abstract] [Full-text]
198. Harvey Cushing's surgical treatment of a pediatric patient with an intraventricular glioma.
     Pediatr Neurosurg, 46(6): 475-9. [Abstract] [Full-text]
199. Anaplastic astroblastoma presenting as massive, sudden-onset, intraparenchymal hemorrhage.
     Pediatr Neurosurg, 46(6): 457-61. [Abstract] [Full-text]
200. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
     Lancet Oncol, 12(6): 583-93. [Abstract] [Full-text]
201. Distress in patients with newly diagnosed brain tumours.
     Psychooncology, 20(6): 623-30. [Abstract] [Full-text]
202. Epstein-Barr virus-associated primary central nervous system lymphoma in a patient with adult T-cell leukemia / lymphoma.
     J Dermatol, 38(6): 575-80. [Abstract] [Full-text]
203. The role of Pygopus 2 in rat glioma cell growth.
     Med Oncol, 28(2): 631-40. [Abstract] [Full-text]
204. β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells.
     Med Oncol, 28(2): 608-14. [Abstract] [Full-text]

© 2004-2012 Brain Cancer Research Today. All Rights Reserved.